MYOMA
MCID: MYM001
MIFTS: 53

Myoma (MYOMA)

Categories: Cancer diseases, Muscle diseases, Reproductive diseases

Aliases & Classifications for Myoma

MalaCards integrated aliases for Myoma:

Name: Myoma 12 54 43 15 71
Neoplasms, Muscle Tissue 43 71
Muscle Benign Neoplasm 12 15
Myomatous Neoplasm 12 71
Benign Neoplasm of the Muscle 12
Muscle Tissue Neoplasm 12
Neoplasm of Muscle 12
Muscle Neoplasms 54
Muscle Neoplasm 12
Myomatous Tumor 12
Myomas 15

Classifications:



External Ids:

Disease Ontology 12 DOID:2691 DOID:461
NCIt 49 C4063 C4882
SNOMED-CT 67 66357004 92237006
ICD10 32 D21
UMLS 71 C0027086 C0027664 C0282606

Summaries for Myoma

Disease Ontology : 12 A muscle benign neoplasm that is characterized as benign hyperplastic lesions of uterine smooth muscle cells.

MalaCards based summary : Myoma, also known as neoplasms, muscle tissue, is related to uterus leiomyosarcoma and amenorrhea, and has symptoms including muscle weakness, myoclonus and myalgia. An important gene associated with Myoma is PGR (Progesterone Receptor), and among its related pathways/superpathways are Development Angiotensin activation of ERK and Pathways in cancer. The drugs Leuprolide and Dimenhydrinate have been mentioned in the context of this disorder. Affiliated tissues include uterus, breast and smooth muscle, and related phenotypes are homeostasis/metabolism and cellular

Wikipedia : 74 Myomas are benign, monoclonal tumors of the smooth muscle cells of the myometrium. They are composed of... more...

Related Diseases for Myoma

Diseases related to Myoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 372)
# Related Disease Score Top Affiliating Genes
1 uterus leiomyosarcoma 32.1 PGR CALD1 CALCA
2 amenorrhea 31.4 LEP GNRH1 CYP19A1
3 leiomyoma 31.3 PGR MED12 HMGA2 GNRH1 FH ESR1
4 endometriosis 31.3 PGR MUC16 GNRH1 ESR1 CYP19A1
5 adenomyosis 31.3 PGR OXT GNRH1 ESR1 CYP19A1
6 intravenous leiomyomatosis 31.2 PGR ESR1 CALD1
7 ovarian cyst 31.1 MUC16 GNRH1 CYP19A1
8 leiomyosarcoma 31.1 PGR MED12 HMGA2 FH ESR1
9 endometrial stromal sarcoma 30.9 PGR ESR1 CYP19A1 CALD1
10 benign metastasizing leiomyoma 30.9 PGR CYP19A1
11 endometrial hyperplasia 30.9 PGR KRAS ESR1 CYP19A1
12 leiomyomatosis 30.8 PGR MED12 GNRH1 FH ESR1
13 endometritis 30.7 PGR OXT ESR1
14 pleomorphic lipoma 30.6 PGR HMGA2
15 adenomyoma 30.6 PGR MED12 GNRH1 ESR1 CALD1
16 cellular leiomyoma 30.6 MUC16 MED12 CALD1
17 pelvic organ prolapse 30.5 PGR MFN2 ESR1
18 endometrial adenocarcinoma 30.5 PGR KRAS ESR1 EGFR
19 endometrial cancer 30.5 PGR MUC16 KRAS GNRH1 ESR1 EGFR
20 carcinosarcoma 30.5 PGR KRAS EGFR
21 vaginal discharge 30.4 PGR OXT GNRH1 ESR1 CYP19A1
22 papillary carcinoma 30.4 PGR ESR1 CALCA
23 vaginal cancer 30.4 PGR ESR1 CALD1
24 in situ carcinoma 30.3 PGR ESR1 EGFR CYP19A1
25 estrogen excess 30.3 PGR GNRH1 ESR1 CYP19A1
26 endometriosis of ovary 30.3 PGR GNRH1 ESR1 CYP19A1
27 liver leiomyoma 30.3 PGR ESR1
28 hemometra 30.3 OXT MFN2
29 atypical polypoid adenomyoma 30.3 MED12 CALD1
30 ovarian serous cystadenocarcinoma 30.2 PGR MUC16 KRAS EGFR
31 leiomyoma cutis 30.2 MED12 FH
32 breast fibroadenoma 30.1 PGR MED12 HMGA2 ESR1 CYP19A1
33 smooth muscle tumor 30.1 PGR MED12 HMGA2 FH ESR1 CALD1
34 leiomyoma, uterine 30.1 PGR OXT MUC16 MED12 HPSE2 HMGA2
35 cervical incompetence 30.0 OXT MFN2
36 vulvar leiomyoma 30.0 PGR HMGA2 ESR1 CALD1
37 bizarre leiomyoma 29.8 PGR MED12 FH ESR1 CALD1
38 ovarian disease 29.8 PGR MUC16 LEP KRAS GNRH1 ESR1
39 bladder leiomyoma 29.5 GNRH1 CALD1
40 skeletal muscle neoplasm 12.3
41 dartoic leiomyoma 11.4
42 carney complex variant 11.2
43 skeletal muscle cancer 11.2
44 muscle cancer 11.2
45 mixed endometrial stromal and smooth muscle tumor 11.2
46 myofibroma 10.7
47 glassy cell carcinoma of the cervix 10.7 PGR ESR1
48 bartholin's gland adenoid cystic carcinoma 10.7 PGR ESR1
49 chronic tympanitis 10.7 PGR ESR1
50 bartholin's gland adenoma 10.6 PGR ESR1

Graphical network of the top 20 diseases related to Myoma:



Diseases related to Myoma

Symptoms & Phenotypes for Myoma

UMLS symptoms related to Myoma:


muscle weakness, myoclonus, myalgia, torticollis, muscle cramp, muscle rigidity, muscle spasticity

MGI Mouse Phenotypes related to Myoma:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.4 CYP19A1 DNAJB7 EGFR EPO ESR1 FH
2 cellular MP:0005384 10.35 CYP19A1 EGFR EPO ESR1 FH KITLG
3 cardiovascular system MP:0005385 10.32 CYP19A1 EGFR EPO ESR1 KITLG KRAS
4 growth/size/body region MP:0005378 10.31 CYP19A1 EGFR ESR1 GNRH1 HPSE2 KITLG
5 integument MP:0010771 10.29 CYP19A1 DNAJB7 EGFR EPO ESR1 GNRH1
6 mortality/aging MP:0010768 10.27 EGFR EPO ESR1 FH HPSE2 KITLG
7 endocrine/exocrine gland MP:0005379 10.25 CYP19A1 EGFR ESR1 GNRH1 KITLG KRAS
8 digestive/alimentary MP:0005381 10.22 CYP19A1 EGFR ESR1 GNRH1 HPSE2 KITLG
9 embryo MP:0005380 10.21 EGFR EPO ESR1 KITLG KRAS LEP
10 nervous system MP:0003631 10.11 CYP19A1 EGFR ESR1 GNRH1 KITLG KRAS
11 limbs/digits/tail MP:0005371 10.1 EGFR EPO ESR1 KITLG KRAS LEP
12 liver/biliary system MP:0005370 10.08 CYP19A1 EGFR EPO ESR1 GNRH1 KITLG
13 muscle MP:0005369 10.03 CYP19A1 EGFR EPO ESR1 KRAS LEP
14 neoplasm MP:0002006 10.01 EGFR ESR1 GNRH1 KITLG KRAS LEP
15 normal MP:0002873 9.97 CYP19A1 EGFR EPO ESR1 GNRH1 KRAS
16 renal/urinary system MP:0005367 9.81 CYP19A1 EGFR ESR1 FH GNRH1 HPSE2
17 pigmentation MP:0001186 9.73 CYP19A1 EGFR KITLG KRAS LEP MFN2
18 reproductive system MP:0005389 9.65 CYP19A1 EGFR ESR1 GNRH1 KITLG KRAS
19 skeleton MP:0005390 9.4 CYP19A1 EGFR EPO ESR1 GNRH1 KITLG

Drugs & Therapeutics for Myoma

Drugs for Myoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 189)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
2
Dimenhydrinate Approved Phase 4 523-87-5 441281
3
Dienogest Approved Phase 4 65928-58-7
4
Desogestrel Approved Phase 4 54024-22-5 40973
5
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
6
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4 62-90-8 229455
7
Letrozole Approved, Investigational Phase 4 112809-51-5 3902
8
Dinoprostone Approved Phase 4 363-24-6 5280360
9
Morphine Approved, Investigational Phase 4 57-27-2 5288826
10
Tranexamic Acid Approved Phase 4 1197-18-8 5526
11
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
12
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
13
Nandrolone Experimental, Investigational Phase 4 434-22-0 9904
14 Ulipristal acetate Phase 4 126784-99-4
15 Fertility Agents Phase 4
16 Anabolic Agents Phase 4
17 Androgens Phase 4
18 Carboxymethylcellulose Sodium Phase 4
19 Contraceptive Agents, Male Phase 4
20 Estrogens Phase 4
21 Aromatase Inhibitors Phase 4
22 Steroid Synthesis Inhibitors Phase 4
23 Estrogen Receptor Antagonists Phase 4
24 Estrogen Antagonists Phase 4
25 Vasoconstrictor Agents Phase 4
26 Natriuretic Agents Phase 4
27 Arginine Vasopressin Phase 4
28 Vasopressins Phase 4
29 Anti-Arrhythmia Agents Phase 4
30 Central Nervous System Depressants Phase 4
31 Anesthetics, Local Phase 4
32 Sodium Channel Blockers Phase 4
33 Diuretics, Potassium Sparing Phase 4
34 Hemostatics Phase 4
35 Coagulants Phase 4
36 Antifibrinolytic Agents Phase 4
37 Oxytocics Phase 4
38 Contraceptive Agents Phase 4
39 Luteolytic Agents Phase 4
40 Contraceptives, Oral Phase 4
41 Contraceptives, Postcoital Phase 4
42 Hormone Antagonists Phase 4
43 Hormones Phase 4
44
Arginine Investigational, Nutraceutical Phase 4 74-79-3 6322
45
Simvastatin Approved Phase 3 79902-63-9 54454
46
Iron Approved, Experimental Phase 3 7439-89-6, 15438-31-0 23925 27284
47
Norethindrone Approved Phase 3 68-22-4 6230
48
Alprostadil Approved, Investigational Phase 2, Phase 3 745-65-3 149351 5280723
49
Goserelin Approved Phase 2, Phase 3 65807-02-5, 1233494-97-7 47725 5311128
50
Misoprostol Approved Phase 3 59122-46-2 5282381

Interventional clinical trials:

(show top 50) (show all 141)
# Name Status NCT ID Phase Drugs
1 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Unknown status NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
2 Ulipristal Acetate Versus GnRH Analogue for Myometrial Preservation in Patients With Submucosal Uterine Leiomyoma G2 Unknown status NCT02357563 Phase 4 ulipristal acetate;Leuprolide acetate
3 Advantages of Ulipristal Acetate for the Preoperative Treatment of Hypoechoic Cellular Leiomyomas Unknown status NCT02361905 Phase 4 ulipristal acetate;Leuprolide acetate
4 The Role of Seprafilm Bioresorbable Slurry in the Prevention of Intrauterine Synechiae in Patients Undergoing Hysteroscopic Myomectomy Unknown status NCT01632202 Phase 4
5 Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin Unknown status NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
6 The Effect of UPA on Women Ovarian Reserve Unknown status NCT02361892 Phase 4 ulipristal acetate
7 GYNAECARE MORCELLEX Tissue Morcellator vs. ROTOCUT GI Tissue Morcellator: a Randomized Controlled Study Completed NCT00743080 Phase 4
8 Pilot of Letrozole for Uterine Myomas Completed NCT02470741 Phase 4 Letrozole
9 Single Versus Double Dose Intra-vaginal Prostaglandin E2 "Misoprostol" Prior Abdominal Myomectomy: A Randomized Controlled Study Completed NCT02154932 Phase 4 2 doses 400 microgram misoprostol;single dose misoprostol
10 A Comparison Between Continuous Infusion vs. Patient Controlled Intraabdominal Injection of Local Anesthetics for Treatment of Postoperative Pain After Abdominal Hysterectomy. A Randomized, Double-blind Study. Completed NCT01492179 Phase 4 Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
11 The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids Completed NCT00995878 Phase 4
12 Vasopressin Administration During Laparoscopic Myomectomy: a Randomized Controlled Trial Completed NCT01393704 Phase 4 Vasopressin
13 SIGnificance of Routine Hysteroscopy Prior to a First 'in Vitro Fertilization'(IVF) Treatment Cycle Completed NCT01242852 Phase 4
14 Safety and Efficacy of Intravenous Oxytocin Versus Tranexamic Acid in Reducing Blood Loss During Abdominal Myomectomy; A Randomized Controlled Trial Not yet recruiting NCT03892668 Phase 4 Tranexamic Acid;oxytocin;placebo
15 Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy in Open, Multicenter Phase IV Clinical Studies Terminated NCT03210324 Phase 4 Mifepristone tablets
16 Multi-institution, Randomized Trial for Efficacy and Safety of Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy for the Treatment of Uterine Myoma or Adenomyosis Unknown status NCT01483417 Phase 3
17 A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
18 Evaluation the Effect of Simvastatin on Uterine Leiomyoma Development and Growth in Infertile Patients Unknown status NCT03134157 Phase 3 oral drug and vaginal placebo;oral drug and oral placebo;Vaginal placebo+ oral placebo
19 To Compare to Single-port Access Laparoscopic-assisted Vaginal Hysterectomy (LAVH) and Multiple Ports LAVH: A Randomized Controlled Trial Unknown status NCT01048931 Phase 3
20 A Phase III, Randomised, Parallel Group, Double-blind, Double-dummy, Active Comparator-controlled, Multicenter Study to Assess the Efficacy and Safety of PGL4001 vs GnRH-agonist for Pre-operative Ttt of Symptomatic Uterine Myomas Completed NCT00740831 Phase 3 PGL4001;leuprorelin
21 A Phase III, Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of PGL4001 (Ulipristal) Versus Placebo for Pre-Operative Treatment of Symptomatic Uterine Myomas Completed NCT00755755 Phase 3 PGL4001 (ulipristal) and iron;PGL4001 matching placebo and iron;PGL4001 (ulipristal) and iron
22 Mifepristone 5 mg Versus 10 mg During 6 Months for the Treatment of Uterine Leiomyomata. A Randomized, Double Blinded Clinical Trial. Completed NCT00886873 Phase 2, Phase 3 Mifepristone
23 A Phase III, Multicentre, Randomized, Double-blind Clinical Study, Investigating the Efficacy and Safety of Repeated 12-week Courses of Daily 5mg or 10mg Doses of PGL4001 for the Long-term Management of Symptomatic Uterine Fibroids Completed NCT01629563 Phase 3 PGL4001 5 mg;PGL4001 10 mg
24 Use of Vasopressin Versus Epinephrine to Reduce Hemorrhage During Myomectomy: a Randomized Controlled Trial Completed NCT01861015 Phase 3 Epinephrine;Vasopressin
25 Placebo-controlled,Doubled,Randomized Trial Evaluating the Effect of Intravenous Ascorbic Acid on Intraoperative Blood Loss in Women Undergoing Laparoscopic Myomectomy Completed NCT01715597 Phase 3 ascorbic acid;Normal saline
26 Single-port Laparoscopic Myomectomy Using Barbed Suture Versus Multi-port One: a Multi-center Randomized Controlled Trial Completed NCT01984632 Phase 3
27 Randomized Controlled Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy Completed NCT01064128 Phase 3
28 A Phase III, Multicentre, Clinical Study Investigating the Efficacy and Safety of 3-months Open-label Treatment With PGL4001, Followed by a Randomised, Double-blind Placebo Controlled Period of 10 Days Treatment With Progestin, in Subjects With Myomas and Heavy Uterine Bleeding. Completed NCT01156857 Phase 3 PGL4001, placebo;PGL4001, progestin
29 A Phase III, Multicentre, Clinical Study Investigating the Efficacy and Safety of Three Successive Periods of 3-month Open-label PGL4001 Treatment, Each Followed by Ten Days of Double-blind Treatment With Progestin or Placebo and a Drug-free Period Until Return of Menses, in Subjects With Myomas and Heavy Uterine Bleeding Completed NCT01252069 Phase 3 PGL4001, placebo, drug free period;PGL4001, progestin, drug free period
30 A Phase III, Multicentre, Extension Study Investigating the Efficacy and Safety of Repeated Intermittent 3-month Courses of Open-label Administration of Ulipristal Acetate, in Subjects With Symptomatic Uterine Myomas and Heavy Uterine Bleeding Completed NCT01642472 Phase 3 Ulipristal Acetate - open label
31 Phase 1 Study of Misoprostol in Reducing Intraoperative Bleeding in Myomectomy Operations Completed NCT02061657 Phase 3 Misoprostol;Placebo( for misoprostol)
32 Mifepristone 5 mg Versus 10 mg for the Treatment of Uterine Leiomyomata. A Randomized, Double Blinded Clinical Trial. Completed NCT00712595 Phase 2, Phase 3 Mifepristone;Mifepristone
33 Efficacy of Transcervical Vasopressin Injection VersusVaginal Misoprostol During Hysteroscopic Myomectomy in Reducing Operative Blood Loss and Operation Time: A Randomized Trial. Completed NCT03930069 Phase 2, Phase 3 Misoprostol;Vasopressin
34 Clinical Trial Protocol for Therapeutic MRI-guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids in a 3T MRI Scanner Completed NCT01064960 Phase 3
35 Aromatase Inhibitors or Gonadotropin-releasing Hormone Agonists for the Management of Uterine Adenomyosis: A Randomized Controlled Trial Completed NCT01218581 Phase 2, Phase 3 received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
36 Single Blinded Randomized Study of Volume Reduction of Uterine Fibroids After Uterine Artery Embolization Versus Computer Tomography or Ultrasound Guided Percutaneous Microwave Ablation Evaluated by Magnetic Resonance Imaging Recruiting NCT02942537 Phase 2, Phase 3
37 the Effect of Misoprostol on Intra-operative Blood Loss During Myomectomy Operation Recruiting NCT03483142 Phase 3 Misoprostol;Placebos
38 Efficacy and Safety of Pre-operative Vaginal Misoprostol in Reduction of Intraoperative Blood Loss During Myomectomy. Amulticentre Single Blind Randomized Trial. Recruiting NCT03509168 Phase 2, Phase 3 Misoprostol Pfizer Brand
39 A Phase 3 Randomized Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-905) Recruiting NCT03924895 Phase 3 Pembrolizumab
40 A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy Versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-866) Recruiting NCT03924856 Phase 3 Pembrolizumab;Gemcitabine;Cisplatin;Placebo
41 Uterus Transplantation From Live Donors and From Deceased Donors - Clinical Study Recruiting NCT03277430 Phase 3 Tacrolimus
42 A Randomized Controlled Trial of Hand-assisted Laparoscopic Myomectomy Versus Abdominal Myomectomy: Surgical Outcomes and Patient Satisfactions Terminated NCT01858454 Phase 3
43 Treatment of Uterine Myoma With 2.5 or 5 mg Mifepristone Daily During 3 Months With 9 Months Post-treatment Follow-up. Randomized Clinical Trial. Terminated NCT01786226 Phase 2, Phase 3 Oral administration of mifepristone 2.5 mg daily for three months;Oral administration of mifepristone 5 mg daily for three months
44 A Controlled Randomized Multicenter Study to Assess the Safety and Performance of Adhibit™ Adhesion Prevention Gel in Myomectomy Surgery Completed NCT00562471 Phase 1, Phase 2
45 Laparoscopic Myomectomy Using Barbed or Conventional Sutures . A Randomized Controlled Trial Completed NCT02166411 Phase 2
46 The Efficacy and Safety of a New Cross-linked Hyaluronan Hydrogel in the Reduction of Postsurgical Adhesions After Laparoscopic Gynecological Surgery: a Randomized Controlled Trial Completed NCT02166554 Phase 1, Phase 2
47 Fertility After Uterine Artery Embolisation for the Treatment of Leiomyomas Completed NCT00839722 Phase 2
48 Embryo Transfer: Embryo Expulsion and Outcome Completed NCT00905788 Phase 1, Phase 2
49 Open Label Phase II Clinical Trial of Myoma Immunotherapy Recruiting NCT03550703 Phase 2
50 Comparative Controlled Trial of Treatment of Minor Unexpected Uterine Cavity Abnormalities Diagnosed by Office Hysteroscopy Screening in Women Indicated for IVF Terminated NCT00830401 Phase 2 Ofloxacinum/Doxycycline

Search NIH Clinical Center for Myoma

Cochrane evidence based reviews: myoma

Genetic Tests for Myoma

Anatomical Context for Myoma

MalaCards organs/tissues related to Myoma:

40
Uterus, Breast, Smooth Muscle, Ovary, Cervix, Lung, Bone

Publications for Myoma

Articles related to Myoma:

(show top 50) (show all 3674)
# Title Authors PMID Year
1
Minimally invasive approach for myomectomy. 54 61
20414845 2010
2
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. 54 61
19135657 2010
3
Interventions to reduce haemorrhage during myomectomy for fibroids. 54 61
19588371 2009
4
The aromatase expression in myomas and myometriums of women in reproduction and perimenopausal age. 54 61
20164038 2009
5
A systematic review of randomized controlled trials to reduce hemorrhage during myomectomy for uterine fibroids. 54 61
17894936 2008
6
Aromatase expression in the eutopic endometrium of myomatous uteri: the influence of the menstrual cycle and oral contraceptive use. 54 61
17616855 2007
7
Interventions to reduce haemorrhage during myomectomy for fibroids. 54 61
17253552 2007
8
Studies on leptin and leptin receptor gene expression in myometrium and uterine myomas of gnRH analogue-treated women. 54 61
17009630 2006
9
Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors. 54 61
15377824 2005
10
Proliferative activity and level of steroid hormone receptors in the myometrium and myoma nodes in different phases of menstrual cycle. 54 61
14714093 2003
11
Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14). 54 61
11788889 2002
12
Levels of estrogen and progesterone receptors in the myometrium and leiomyoma tissue after suppression of estrogens with gonadotropin releasing hormone analogs. 54 61
12227888 2001
13
Tamoxifen treatment and gynecologic side effects: a review. 54 61
11336777 2001
14
Advances in uterine leiomyoma research: the progesterone hypothesis. 54 61
11035984 2000
15
Differential efficacy of gonadotropin-releasing hormone (GnRH) agonist treatment on pedunculated and degenerated myomas: a retrospective study of 630 women. 54 61
15512637 2000
16
Combining myoma coagulation with endometrial ablation/resection reduces subsequent surgery rates. 54 61
10694070 1999
17
Correlation between the growth of uterine leiomyomata and estrogen and progesterone receptor content in needle biopsy specimens. 54 61
9806586 1998
18
Cryomyolysis, a new procedure for the conservative treatment of uterine fibroids. 54 61
9454874 1998
19
[Value of premedication with gonadotropin releasing hormone agonists before transcervical resection of solitary submucous myoma]. 54 61
9206552 1996
20
[Research on the relationship between estrogen receptor, progesterone receptor, cell proliferation associated antigen in uterine leiomyoma and nuclear body density of myoma, serum reproductive hormone concentrations]. 54 61
8745507 1995
21
Progesterone: a critical role in the pathogenesis of uterine myomas. 54 61
7847524 1995
22
Production and characterization of monoclonal antibodies to shark cartilage proteoglycan. 54 61
7540474 1994
23
Estrogen and progesterone receptor content of enucleated uterine myomata after luteinizing hormone-releasing hormone. Analogue depot therapy. 54 61
8160541 1994
24
Pulmonary lymphangioleiomyomatosis. 54 61
8369788 1993
25
[Effect of decapeptyl (D-TrpG GnPh) on estrogen receptors, progesterone receptors and tissue levels of estrogens (non-conjugated and sulfate-conjugated) in patients with uterine myoma]. 54 61
2148976 1990
26
Progestin and antiprogestin interactions with progesterone receptors in human myomas. 54 61
1969820 1990
27
[The mechanism of the therapeutic effect of norethisterone in hyperplastic diseases of the endo- and myometrium in women of reproductive age]. 54 61
2198696 1990
28
Immunoreactive and estrogen-binding estrogen receptors, and progestin receptor levels in uterine leiomyomata and their parental myometrium. 54 61
2245811 1990
29
Inferior Mesenteric Arterial Supply to a Symptomatic Uterine Myoma. 61
31299359 2020
30
Laparoscopic In-Bag Morcellation Compared with Conventional Morcellation of Myomas and Uterus with Myomas. 61
32030009 2020
31
Pregnancy outcome after emergency uterine artery embolisation for management of intractable haemorrhage associated with laparoscopic-assisted myomectomy. 61
32027204 2020
32
Robotic single-site myomectomy: A hybrid technique reducing operative time and blood loss. 61
31840384 2020
33
Safety and efficacy of contained manual morcellation during laparoscopic or robotic gynecological surgery. 61
31755560 2020
34
Critically High Carboxyhemoglobin Level following Extensive Hysteroscopic Myomectomy. 61
31574314 2020
35
CXCL12 Attracts Bone Marrow-Derived Cells to Uterine Leiomyomas. 61
32020550 2020
36
More Than a Myoma: A Review of Myomatous Erythrocytosis Syndrome. 61
30904341 2020
37
What does non-eligibility for myoma surgery mean in the context of sequential prescription of ulipristal acetate? 61
31972353 2020
38
Preoperative Treatment with Ulipristal Acetate before Outpatient Hysteroscopic Myomectomy. 61
31940645 2020
39
Predictors of Overnight Admission After Laparoscopic Myomectomy in a High-Volume Minimally Invasive Gynecologic Surgery Setting. 61
30936030 2020
40
Laparoscopic Myomectomy: An Alternative Approach to Tackling Submucous Myomas? 61
30926366 2020
41
Temporary Ligation of the Uterine Artery at Its Origin Using a Removable "Shoelace" Knot. 61
31252055 2020
42
Intrauterine adhesion prevention with Malecot catheter after hysteroscopic myomectomy: A novel approach. 61
32039801 2020
43
Transvaginal Ultrasound and Doppler Features of Intraligamental Myomas. 61
31944342 2020
44
Role of transvaginal ultrasound-guided biopsy in gynecology. 61
31645428 2020
45
Laparoscopic-assisted myomectomy: Surgery center versus outpatient hospital. 61
31997510 2020
46
T-cadherin inhibits invasion and migration of endometrial stromal cells in endometriosis. 61
31886853 2020
47
ZC3H7B-BCOR high-grade endometrial stromal sarcoma may present as myoma nascens with cytoplasmic signet ring cell change. 61
31938824 2020
48
Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids. 61
32012826 2020
49
The differential distribution of bacteria between cancerous and noncancerous ovarian tissues in situ. 61
31954395 2020
50
The importance of pseudocapsule preservation during hysteroscopic myomectomy. 61
31585677 2019

Variations for Myoma

Expression for Myoma

Search GEO for disease gene expression data for Myoma.

Pathways for Myoma

Pathways related to Myoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.59 KRAS KITLG EPO EGFR CALD1
2 12.46 KRAS KITLG FH ESR1 EPO EGFR
3 12.07 KRAS HPSE2 ESR1 EGFR
4
Show member pathways
12.01 OXT KRAS EGFR CALD1 CALCA
5 11.86 KRAS ESR1 EGFR CYP19A1
6
Show member pathways
11.29 PGR KRAS ESR1 EGFR
7 11.26 KRAS ESR1 EGFR
8 10.23 KRAS EPO EGFR
9 9.92 ESR1 CYP19A1

GO Terms for Myoma

Cellular components related to Myoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 OXT MUC16 LEP KITLG GNRH1 EPO

Biological processes related to Myoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.06 PGR OXT LEP KRAS KITLG GNRH1
2 negative regulation of apoptotic process GO:0043066 9.8 LEP KITLG HMGA2 GNRH1 EPO EGFR
3 positive regulation of protein kinase B signaling GO:0051897 9.73 LEP KITLG ESR1 EGFR
4 positive regulation of cell proliferation GO:0008284 9.73 LEP KRAS KITLG HPSE2 EPO EGFR
5 positive regulation of MAP kinase activity GO:0043406 9.65 KRAS KITLG EGFR
6 ovulation cycle GO:0042698 9.51 GNRH1 EGFR
7 response to prostaglandin E GO:0034695 9.49 OXT GNRH1
8 ovulation from ovarian follicle GO:0001542 9.46 PGR LEP
9 response to estradiol GO:0032355 9.46 OXT LEP ESR1 EGFR
10 negative regulation of calcium ion transport into cytosol GO:0010523 9.37 EPO CALCA
11 positive regulation of cold-induced thermogenesis GO:0120162 9.26 OXT MFN2 LEP FH
12 female pregnancy GO:0007565 8.92 OXT LEP KRAS GNRH1

Molecular functions related to Myoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.02 OXT LEP GNRH1 EPO CALCA
2 nitric-oxide synthase regulator activity GO:0030235 8.96 ESR1 EGFR

Sources for Myoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....